~~<i id='18BF88F9CB'><strike id='18BF88F9CB'><tt id='18BF88F9CB'><pre id='18BF88F9CB'></pre></tt></strike></i>~~

Home» comprehensive» explore

explore

author：knowledge 2025-09-29 11:01:18 Page View：345

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Treeline, Josh Bilenker's next biotech, is cloaked in mystery
Next article： Drug repurposing or repositioning? The language matters

knowledge

Hepatitis C has a cure — but many Americans still lack access to it

AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

UnitedHealth financials solid despite Change Healthcare cyberattack

AdobeHospitalsandmedicalgroupssaythey’restillreelingfromtheeffectsofthecyberattackonaUnitedHealthGro

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

2:18Seaotter841floatsinthispictureobtainedfromsocialmedia,inCowellsCove,SantaCruz,California,U.S.,Ju